Navigation Links
KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
Date:5/30/2008

KV Expects Filings To Be Completed Within Automatic Form 10-K Extension

Period

ST. LOUIS, May 30 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded products and generic/non-branded prescription pharmaceuticals, announced today that it expects to complete and file its fiscal 2008 Form 10-K with the Securities and Exchange Commission within the automatic extension period ending June 16, 2008 pursuant to a Form 12b-25 filed by the Company today. We also expect the fiscal 2008 Form 10-Q's will be filed by June 16, 2008.

Since the Company filed its fiscal 2007 Form 10-Q's and Form 10-K in March 2008, which incorporated the restatement of 11 years of financial statements and additional interim financial information, the Company has focused on preparing its Form 10-Q's for the first three quarters of fiscal 2008 and Form 10-K for the full fiscal year ended March 31, 2008. Although the Company had sought diligently to file the Form 10-K within 60 days after the end of its fiscal year, the time provided by the automatic extension period to June 16, 2008 is necessary to afford sufficient review by the parties involved.

With the completion of these filings, the Company will be in compliance with all Securities and Exchange Commission periodic filing requirements.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary. '/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ILADELPHIA, Nov. 21 NursingCenter....ng education and peer reviewed content, has been,...its 350,000 registered,users. Powered by Lippinco... now,provides over 900 peer-reviewed continuing e...icles from more than 50 leading nursing journals.,...
(Date:11/21/2008)...LUMBIA, S.C., Nov. 21 U...ttee for Quality Assurance (NCQA) ranked BlueChoic... of America,s Best Health Plans(TM), published in ... , The respected annual ranking ranks the na..., member satisfaction and NCQA accreditation score...
(Date:11/21/2008)...ANKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/... for medical intervention in treating 88 percent o...ercent of Americans treated for a chronic conditio...spending and 75 percent of all medical costs. A p... years by Medco Health Solutions, Inc. (NYSE: MH...
(Date:11/21/2008)...udy found 2 popular drugs do not cause genetic dam... Nov. 21 (HealthDay News) -- Two popular medicatio...sorder (ADHD) do not cause genetic damage linked t...tudy says. , The study, done by researchers at ...stitutes of Health, counters a previous one that r...
Breaking Medicine News(10 mins):Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2
... Daniel Musher, MD, studied the records of all 170... at a Texas Veterans Affairs medical center from ... with pneumonia may be at serious risk of new or w...at 19.4 percent of them had a heart attack or othe...
... geneticists say that they have developed a faster... mutants in large, non-gene stretches of DNA. The...ause diseases can result not only from mutant gene...DNA that controls genes. "Diseases are known to o...
... disease that can cause blindness and affects mill...ely get past the blood-brain barrier making it an...Sudipta Seal, an engineering professor with appoin...ssing and Analysis Center and the Nanoscience Tech...
...sts that playing with candy cigarettes may favorab... future cigarette smokers . The study, reported ...at in a nationally representative sample of 25,887... never consumed candy cigarettes were 12% in curre...
Other Medicine News:Health News:Pneumonia Patients Develop Heart Risks 2Health News:Boffins Develop New Technique to Hunt Illness-causing Mutants in Non-gene DNA 2Health News:Nanoparticle in the Treatment of Glaucoma 2Health News:The Danger in Candy Cigarettes 2
(Date:11/20/2008)..., Norway, November 20 The Scandina...ma has announced results of studies on its,lead a... in Washington, DC,the studies showed that the n...eriocidal effect, significantly better towards kil...enes than marketed gold standard drugs. In,additi...
(Date:11/19/2008)...cientists report basic findings on critical enzyme... better treat an array of disorders , , MEM...cientists at St. Jude Children,s Research Hospital...f the body,s enzyme workhorses called calpains. ,...alpains function in many cellular processes, inclu...
(Date:11/18/2008)...vember 19 NeuroDiscovery... provider and drug development Company,and Sosei...65), a leading,international biopharmaceutical co...enting further pivotal pre-clinical efficacy data ... potential therapy for neuropathic pain and has,s...
(Date:11/18/2008)...ung Association,s 2008 Faces of Influenza survey u...ized against influenza; Mother and Gold Medalist K...NGTON, Nov. 18 While 78 percent of... severe and potentially life-threatening disease t...their families will get vaccinated this season, ac...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 1627 1Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 1627 2Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 1627 3Real World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS 28R 29 Express 28TM 29 Stent 4258 1Real World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS 28R 29 Express 28TM 29 Stent 4258 2Real World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS 28R 29 Express 28TM 29 Stent 4258 3Real World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS 28R 29 Express 28TM 29 Stent 4258 4TRITON TIMI 38 Stent Analysis Favors Prasugrel 1623 1TRITON TIMI 38 Stent Analysis Favors Prasugrel 1623 2TRITON TIMI 38 Stent Analysis Favors Prasugrel 1623 3ISAR REACT 3 Pits Bivalirudin vs Unfractionated Heparin in PCI 1618 1ISAR REACT 3 Pits Bivalirudin vs Unfractionated Heparin in PCI 1618 2ISAR REACT 3 Pits Bivalirudin vs Unfractionated Heparin in PCI 1618 3
...ate Role of Innovative New Treatment in Population...witzerland, April 23, 2007 /PRNewswire/ -- A new R..., a continuous,erythropoietin receptor activator, ...test growing groups of patients with chronic,kidne...lysis. In,this analysis, MIRCERA treatment kept Hb...
...ril 23, 2007 /PRNewswire/ -- Sirion Therapeutics,a...ipeline,compounds, ST-601 (difluprednate) and ST-6...nual meeting of The Association for,Research in Vi...L.,In addition to these presentations, the company... ST-601 (difluprednate) is currently being evaluat...
Other Medicine Technology:Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 2Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 3Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 4Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 5Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4
...generations. Most gels can be dried by positioning... covering them with wet semi-permeable cellophane ...ane flat. Tut's Tombs also produce great fluorogra...er than the gel to be dried. Note our cellophane i...
...generations. Most gels can be dried by positioning... covering them with wet semi-permeable cellophane ...ane flat. Tut's Tombs also produce great fluorogra...er than the gel to be dried. Note our cellophane i...
...generations. Most gels can be dried by positioning... covering them with wet semi-permeable cellophane ...ane flat. Tut's Tombs also produce great fluorogra...er than the gel to be dried. Note our cellophane i...
...generations. Most gels can be dried by positioning... covering them with wet semi-permeable cellophane ...ane flat. Tut's Tombs also produce great fluorogra...er than the gel to be dried. Note our cellophane i...
Medicine Products: